Millipore Sigma Vibrant Logo

HNDG3MAG-36K MILLIPLEX MAP Human Neurodegenerative Disease Magnetic Bead Panel 3 - Neuroscience Multiplex Assay

The analytes available for this multiplex kit are: BDNF, Cathepsin D, MPO, NCAM, PAI-1 (total), PDGF-AA, PDGF-AB/BB, RANTES, sICAM-1, sVCAM-1.

MSDS (material safety data sheet) or SDS, CoA and CoQ, dossiers, brochures and other available documents.
Key Applications: Multiplexing Detection Methods: Luminex xMAP Research Category: Neuroscience Research Sub-Category: Alzheimer's Disease, Nervous System, Neurodegenerative Diseases
View Products on Sigmaaldrich.com
HNDG3MAG-36K
Design And Price Your Kit

Overview

Replacement Information

Key Spec Table

Analytes AvailableSpecies ReactivityKey ApplicationsDetection Methods
BDNF Cathepsin D MPO NCAM PAI-1 (total) PDGF-AA PDGF-AB/BB RANTES sICAM-1 sVCAM-1 HMplexLuminex xMAP
Description
Catalogue NumberHNDG3MAG-36K
Trade Name
  • MILLIPLEX
DescriptionMILLIPLEX MAP Human Neurodegenerative Disease Magnetic Bead Panel 3 - Neuroscience Multiplex Assay
OverviewThe MILLIPLEX® MAP Human Neurodegenerative Magnetic Bead Panel 3 (HNDG3MAG-36K) is to be used for the simultaneous quantification of the following 10 analytes in any combination: BDNF, Cathepsin D, MPO, NCAM, PAI-1 (total), PDGF-AA, PDGF-AB/BB, RANTES, sICAM-1, and sVCAM-1. This kit may be used for the analysis of all above analytes in human serum, plasma, and cerebrospinal fluid samples.

References:
Bipolar Disord. 2016 Aug;18(5):433-9. doi: 10.1111/bdi.12418.
Inter-relation between brain-derived neurotrophic factor and antioxidant enzymes in bipolar disorder.
Mansur RB, Santos CM, Rizzo LB, Cunha GR1, Asevedo E, Noto MN, Pedrini M, Zeni M, Cordeiro Q, McIntyre RS, Brietzke E
Background InformationNeurodegenerative disease is a condition characterized by the deterioration of neurons or their myelin sheath over time in the brain and/or spinal cord. These neurons are responsible for such everyday activities as processing sensory information, making decisions, and controlling movement. Because these cells are not easily regenerated, excessive cumulative damage can lead to age-related diseases such as Alzheimer's and Parkinson's disease, as well as other conditions such as amyotrophic lateral sclerosis (ALS) and epilepsy. These disorders are devastating and expensive, both on a personal and global level, and as population demographics continue to change, a therapeutic solution is critical. Consequently, research is underway to identify biomarkers that will help scientists not only understand the pathogenesis of neurodegenerative disease, but also identify people with these disorders before the onset of symptoms and potentially provide new therapeutic tools.
References
Product Information
Detection methodLuminex xMAP
ConfigurationDesign your multiplex kit by choosing available analytes within this panel.
Precision, %
  • Intra-assay:<10
  • Inter-assay: <15
Panel TypeMAGNETIC Neuroscience
Quality LevelMQ200
Applications
ApplicationThe analytes available for this multiplex kit are: BDNF, Cathepsin D, MPO, NCAM, PAI-1 (total), PDGF-AA, PDGF-AB/BB, RANTES, sICAM-1, sVCAM-1.
Key Applications
  • Multiplexing
Application Notes• This is an overnight assay.
• This assay requires 25 μL of 1:100 diluted serum/plasma or neat CSF per well.
Biological Information
Species Reactivity
  • Human
Analytes Available
  • BDNF
  • Cathepsin D
  • MPO
  • NCAM
  • PAI-1 (total)
  • PDGF-AA
  • PDGF-AB/BB
  • RANTES
  • sICAM-1
  • sVCAM-1
Assay PanelEverything you need in a single kit.
Cross ReactivityCross-reactivity between the antibodies and any of the other analytes in this panel is non-detectable or negligible.
Accuracy
  • BDNF 114%
  • Cathepsin D 111%
  • MPO 100%
  • NCAM 103%
  • PAI-1 (total) 92%
  • PDGF-AA 123%
  • PDGF-AB/BB 137%
  • RANTES 108%
  • sICAM-1 108%
  • sVCAM-1 104%
Physicochemical Information
Sensitivity
  • See kit protocol for individual sensitvities
Standard Curve Range
  • BDNF 2.4-10,000 pg/mL
  • Cathepsin D 24-100,000 pg/mL
  • MPO 24-100,000 pg/mL
  • NCAM 24-100,000 pg/mL
  • PAI-1 (total) 2.4-10,000 pg/mL
  • PDGF-AA 2.4-10,000 pg/mL
  • PDGF-AB/BB 24-100,000 pg/mL
  • RANTES 2-10,000 pg/mL
  • sICAM-1 24-100,000 pg/mL
  • sVCAM-1 61-250,000 pg/mL
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Usage Statement
  • Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Storage and Shipping Information
Storage ConditionsRecommended storage for kit components is 2 - 8°C.
Packaging Information
Material Size96-well plate
Transport Information
Supplemental Information
Specifications
Global Trade Item Number
Catalogue Number GTIN
HNDG3MAG-36K 04053252987564

Documentation

Protocols

Title
Protocol- HNDG3MAG-36K

MILLIPLEX MAP Human Neurodegenerative Disease Magnetic Bead Panel 3 - Neuroscience Multiplex Assay SDS

Title

Safety Data Sheet (SDS) 

References

Reference overviewPub Med ID
Plasma proteins predict conversion to dementia from prodromal disease.
Hye A, Riddoch-Contreras J, Baird AL, Ashton NJ, Bazenet C, Leung R, Westman E, Simmons A, Dobson R, Sattlecker M, Lupton M, Lunnon K, Keohane A, Ward M, Pike I, Zucht HD, Pepin D, Zheng W, Tunnicliffe A, Richardson J, Gauthier S, Soininen H, K³oszewska I, Mecocci P, Tsolaki M, Vellas B, Lovestone S.
Alzheimers Dement. 2014 Nov;10(6):799- 807.e2  2014

25012867 25012867

Brochure

Title
The Power of Biomarker Analysis

Technical Info

Title
96 well Template 2 Up
96 well Template Single
HNDG3MAG-36K xPonent Protocol Template Version 3.1
Quality Control Range Sheet- HNDG3-116 and HNDG3-216
Quality Control: Milliplex Human Neurodegenerative Disease Panel 3 Kit

Posters

Title
Inflammation in Neurodegenerative Diseases
Toxicology in drug discovery and development: Biomarkers and model organisms